While mutations affecting protein-coding regions have been examined across many cancers,
structural variants at the genome-wide level are still poorly defined. Through integrative …

Although systemic androgen deprivation prolongs life in advanced prostate cancer,
remissions are temporary because patients almost uniformly progress to a state of a castration-…

Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that
most commonly evolves from preexisting prostate adenocarcinoma (PCA). Using next-…

Purpose: Although novel agents targeting the androgen–androgen receptor (AR) axis have
altered the treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC), …

Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine prostate
cancer (t-SCNC) are not well characterized in the era of modern androgen receptor (AR)…

The androgen receptor (AR) is a key regulator of prostate growth and the principal drug
target for the treatment of prostate cancer. Previous studies have mapped AR targets and …

A model of human prostate cancer was established to study cellular interaction between
prostate cancer and bone stroma in vivo. In this model, subcutaneous co‐injection of 2 non‐…

Pancreatic cancer is a disease with an extremely poor prognosis. Tumor protein 53-induced
nuclear protein 1 (TP53INP1) is a proapoptotic stress-induced p53 target gene. In this article…

Androgen deprivation therapy (ADT) remains the primary treatment for advanced prostate
cancer. The efficacy of ADT has not been rigorously evaluated by demonstrating suppression …

Background Patients with prostate cancer who have high-risk biochemical recurrence have
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen-…